Share this article
Share this article
NEW YORK, Dec. 18, 2020 /PRNewswire/ Rowley Law PLLC is investigating potential securities law violations by BioTelemetry, Inc. (NASDAQ: BEAT) and its board of directors concerning the proposed acquisition of the company by Royal Philips (NYSE: PHG). Stockholders will receive $72.00 for each share of BioTelemetry stock that they hold. The transaction is valued at approximately $2.8 billion and is expected to close in the first quarter of 2021.
If you are a stockholder of BioTelemetry, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/beat/. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at
Share this article
Share this article
NEW YORK, Dec. 18, 2020 /PRNewswire/ Rowley Law PLLC is investigating potential securities law violations by Seneca Biopharma, Inc. (NASDAQ: SNCA) and its board of directors concerning the merger of the company with Leading BioSciences, Inc. Seneca Biopharma stockholders will own approximately 26.2% of the combined company. The transaction is expected to close in the first half of 2021.
If you are a stockholder of Seneca Biopharma, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/snca/. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of TCF Financial Corporation marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Rowley Law PLLC is investigating potential securities law violations by ZAGG Inc. (NASDAQ: ZAGG) and its board of directors concerning the.
/PRNewswire/ Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors.